Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Stage IV Bladder Cancer AJCC v8

Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Stage IV Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
Epirubicin
Fred Hutchinson Cancer Center
Phase 2BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B
Avelumab
G1 Therapeutics, Inc.
Phase 2CCC
PROPRANOLOL
Emory University
Phase 2CCC

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →